All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901W58" target="_blank" >RIV/61988987:17110/18:A1901W58 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11150/18:10380677 RIV/00179906:_____/18:10380677 RIV/00843989:_____/18:E0107028

  • Result on the web

    <a href="http://dx.doi.org/10.1111/bjh.15092" target="_blank" >http://dx.doi.org/10.1111/bjh.15092</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1111/bjh.15092" target="_blank" >10.1111/bjh.15092</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients

  • Original language description

    We report a multicentre retrospective study that analysed clinical characteristics and outcomes in 117 patients with primary plasma cell leukaemia (pPCL) treated at the participating institutions between January 2006 and December 2016. The median age at the time of pPCL diagnosis was 61years. Ninety-eight patients were treated with novel agents, with an overall response rate of 78%. Fifty-five patients (64%) patients underwent upfront autologous stem cell transplantation (ASCT). The median follow-up time was 50months (95% confidence interval [CI] 33; 76), with a median overall survival (OS) for the entire group of 23 months (95% CI 15; 34). The median OS time in patients who underwent upfront ASCT was 35 months (95% CI 24.3; 46) as compared to 13 months (95% CI 6.3; 35.8) in patients who did not receive ASCT (P=0.001). Multivariate analyses identified age >= 60years, platelet count &lt;= 100x10(9)/l and peripheral blood plasma cell count &gt;= 20x10(9)/l as independent predictors of worse survival. The median OS in patients with 0, 1 or 2-3 of these risk factors was 46, 27 and 12months, respectively (P&lt;0.001). Our findings support the use of novel agents and ASCT as frontline treatment in patients with pPCL. The constructed prognostic score should be independently validated.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    BRITISH JOURNAL OF HAEMATOLOGY

  • ISSN

    0007-1048

  • e-ISSN

    1365-2141

  • Volume of the periodical

    180

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    9

  • Pages from-to

    831-839

  • UT code for WoS article

    000426607200008

  • EID of the result in the Scopus database

    2-s2.0-85042936275